Aspects and Implementation of Pharmaceutical Quality by Design from Conceptual Frameworks to Industrial Applications
文献类型：期刊论文
| 作者 | Yang, Shiwei1,2,3; Hu, Xingming1,3; Zhu, Jinmiao1,3; Zheng, Bin1,3; Bi, Wenjie3; Wang, Xiaohong3; Wu, Jialing3; Mi, Zimeng3; Wu, Yifei3 |
| 刊名 | PHARMACEUTICS
 |
| 出版日期 | 2025-05-08 |
| 卷号 | 17期号:5页码:24 |
| 关键词 | quality by design design of experiments drug development |
| DOI | 10.3390/pharmaceutics17050623 |
| 英文摘要 | Background/Objectives: Quality by Design (QbD) has revolutionized pharmaceutical development by transitioning from reactive quality testing to proactive, science-driven methodologies. Rooted in ICH Q8-Q11 guidelines, QbD emphasizes defining Critical Quality Attributes (CQAs), establishing design spaces, and integrating risk management to enhance product robustness and regulatory flexibility. This review critically examines QbD's theoretical frameworks, implementation workflows, and industrial applications, aiming to bridge academic research and commercial practices while addressing emerging challenges in biologics, advanced therapies, and personalized medicine. Methods: The review synthesizes regulatory guidelines, case studies, and multidisciplinary tools, including Design of Experiments (DoE), Failure Mode Effects Analysis (FMEA), Process Analytical Technology (PAT), and multivariate modeling. It evaluates QbD workflows-from Quality Target Product Profile (QTPP) definition to control strategies-and explores advanced technologies like AI-driven predictive modeling, digital twins, and continuous manufacturing. Results: QbD implementation reduces batch failures by 40%, optimizes dissolution profiles, and enhances process robustness through real-time monitoring (PAT) and adaptive control. However, technical barriers, such as nonlinear parameter interactions in complex systems, and regulatory disparities between agencies hinder broader adoption. Conclusions: QbD significantly advances pharmaceutical quality and efficiency, yet requires harmonized regulatory standards, lifecycle validation protocols, and cultural shifts toward interdisciplinary collaboration. Emerging trends, including AI-integrated design space exploration and 3D-printed personalized medicines, promise to address scalability and patient-centric needs. By fostering innovation and compliance, QbD remains pivotal in achieving sustainable, patient-focused drug development. |
| WOS关键词 | PAT ; MANAGEMENT ; PRODUCT ; PART |
| 资助项目 | Out-standing Youth Research Project for Universities in Anhui Province ; Anhui Quality Engineering Program[2023sdxx060] ; Key Projects of Scientific Research Program of Higher Education Institutions in Anhui Province[2024AH051591] ; Key Projects of Scientific Research Program of Higher Education Institutions in Anhui Province[2023AH051323] ; [2023AH030097] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001495729500001 |
| 出版者 | MDPI |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/317986]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Yang, Shiwei; Zhu, Jinmiao |
| 作者单位 | 1.Hefei Normal Univ, Anhui Prov Engn Lab Dev & Utilizat Med & Edible Na, Hefei 230061, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 3.Hefei Normal Univ, Dept Chem & Chem Engn, Hefei 230061, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yang, Shiwei,Hu, Xingming,Zhu, Jinmiao,et al. Aspects and Implementation of Pharmaceutical Quality by Design from Conceptual Frameworks to Industrial Applications[J]. PHARMACEUTICS,2025,17(5):24. |
| APA | Yang, Shiwei.,Hu, Xingming.,Zhu, Jinmiao.,Zheng, Bin.,Bi, Wenjie.,...&Wu, Yifei.(2025).Aspects and Implementation of Pharmaceutical Quality by Design from Conceptual Frameworks to Industrial Applications.PHARMACEUTICS,17(5),24. |
| MLA | Yang, Shiwei,et al."Aspects and Implementation of Pharmaceutical Quality by Design from Conceptual Frameworks to Industrial Applications".PHARMACEUTICS 17.5(2025):24. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。